Companies: 10,795·Total market cap: $144.5T
Achilles Therapeutics plc

Achilles Therapeutics plc

ACHLNASDAQHealthcare
$1.48
+$0.01(+0.68%)
Market Cap$60828000
P/E Ratio—
52W High$1.51
52W Low$0.63
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Achilles Therapeutics plc (ACHL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001830749 · ACHL · NASDAQ · as of Jun 9, 2026

Filing snapshot

107
Total Filings
15-12G
Latest Form
2025-03-21
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001830749 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2024-04-04
Fiscal Year End
Apr 4, 2024
Accession No.
0000950170-24-041615
Primary Document
achl-20231231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001830749 · Accession 0000950170-24-041615

Latest Key Filings

6-KQuarterly Report
6-K
2025-03-20
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2025-03-21
View
6-KCurrent Report (Foreign Issuer)
6-K
2025-03-20
View
S-8 POSS-8 POS
S-8 POS (REG NUMBER 333-278501)
2025-03-19
View
S-8 POSS-8 POS
S-8 POS (REG NUMBER 333-270344)
2025-03-19
View
S-8 POSS-8 POS
S-8 POS (REG NUMBER 333-263220)
2025-03-19
View
S-8 POSS-8 POS
S-8 POS (REG NUMBER 333-255063)
2025-03-19
View
EFFECTEFFECT
EFFECT
2025-03-11
View
POS AMPOS AM
POS AM
2025-03-11
View
2525
25
2025-03-11
View
6-KCurrent Report (Foreign Issuer)
6-K
2025-02-28
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-13
View
6-KCurrent Report (Foreign Issuer)
6-K
2025-02-04
View
6-KCurrent Report (Foreign Issuer)
6-K
2025-01-06
View
6-KCurrent Report (Foreign Issuer)
6-K
2024-12-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2024-12-02
View
Showing 1–15 of 93 filingsForm 4 / 144 hidden· 107 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001830749  |  Exchange: NASDAQ · Healthcare

Achilles Therapeutics plc (NASDAQ: ACHL) has submitted 107 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001830749, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Achilles Therapeutics plc's most comprehensive regulatory disclosure. The most recent Achilles Therapeutics plc 10-K was filed on 2024-04-04 for fiscal year ending 2024. Historical ACHL 10-K annual reports are available from 2020 through 2024.

Investors researching Achilles Therapeutics plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
SURF SEC Filings →VLNS SEC Filings →HTBX SEC Filings →RPHM SEC Filings →TCRR SEC Filings →SGTX SEC Filings →KRON SEC Filings →ALVR SEC Filings →
→ ACHL Financials→ ACHL Earnings→ ACHL Insider Trades

Frequently Asked Questions

ACHL SEC Filings · 8 questions

Achilles Therapeutics plc (ACHL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 107 filings and access original documents at no cost. Achilles Therapeutics plc's CIK is 0001830749.

ACHL SEC filingsAchilles Therapeutics plc SEC documentsfind ACHL 10-K